Daily Bulletin

Men's Weekly

.

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

  • Written by PR Newswire Asia - Daily Bulletin Au RSS

SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC).

To date, three patients with metastatic TNBC...

Read more: Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of...

Business News

How Thorough Component Inspections Protect Your Supply Chain from Costly Failures

In the modern world, where manufacturing has become highly interconnected, the weakest components of the supply chain can only make the chain as strong as it is. One defective component might cause ...

Daily Bulletin - avatar Daily Bulletin

3PL Logistics in Australia: Strengthening Supply Chains for Growing Businesses

Australia’s vast geography and diverse consumer markets make logistics a critical part of business success. As companies scale and customer expectations rise, many turn to 3pl logistics australia to...

Daily Bulletin - avatar Daily Bulletin

Why Choosing The Right Shopify Web Developer Shapes Long-Term Ecommerce Success

Building a Shopify store that performs reliably over time requires more than surface-level setup. Working with an experienced Shopify web developer ensures that the platform is configured with inten...

Daily Bulletin - avatar Daily Bulletin

Speed Dating For Business